American Association for Cancer Research
00085472can190054-sup-214827_2_supp_5629592_ps6hks.pdf (8.4 MB)

Figure S4 from Mutant IDH Sensitizes Gliomas to Endoplasmic Reticulum Stress and Triggers Apoptosis via miR-183-Mediated Inhibition of Semaphorin 3E

Download (8.4 MB)
journal contribution
posted on 2023-03-31, 02:22 authored by Ying Zhang, Stefan Pusch, James Innes, Kastytis Sidlauskas, Matthew Ellis, Joanne Lau, Tedani El-Hassan, Natasha Aley, Francesca Launchbury, Angela Richard-Loendt, Jasper deBoer, Sheng Chen, Lei Wang, Andreas von Deimling, Ningning Li, Sebastian Brandner

Generation of IDH mutant tumours with adeno Cre mediated recombination


Brain Tumour Charity


Department of Health's NIHR Biomedical Research Centre's


Cancer Research UK



Human astrocytomas and oligodendrogliomas are defined by mutations of the metabolic enzymes isocitrate dehydrogenase (IDH) 1 or 2, resulting in the production of the abnormal metabolite D-2 hydroxyglutarate. Here, we studied the effect of mutant IDH on cell proliferation and apoptosis in a glioma mouse model. Tumors were generated by inactivating Pten and p53 in forebrain progenitors and compared with tumors additionally expressing the Idh1 R132H mutation. Idh-mutant cells proliferated less in vitro and mice with Idh-mutant tumors survived significantly longer compared with Idh-wildtype mice. Comparison of miRNA and RNA expression profiles of Idh-wildtype and Idh-mutant cells and tumors revealed miR-183 was significantly upregulated in IDH-mutant cells. Idh-mutant cells were more sensitive to endoplasmic reticulum (ER) stress, resulting in increased apoptosis and thus reduced cell proliferation and survival. This was mediated by the interaction of miR-183 with the 5′ untranslated region of semaphorin 3E, downregulating its function as an apoptosis suppressor. In conclusion, we show that mutant Idh1 delays tumorigenesis and sensitizes tumor cells to ER stress and apoptosis. This may open opportunities for drug treatments targeting the miR-183–semaphorin axis. The pathologic metabolite 2-hydroxyglutarate, generated by IDH-mutant astrocytomas, sensitizes tumor cells to ER stress and delays tumorigenesis.